Cat: IPD-X13859

Recombinant Mouse BCA-1/CXCL13 Protein(HEK293), N-His

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • Gene name

    BCA-1/CXCL13

  • 简介

    CXCL13, known as BCA-1 (B cell-attracting chemokine 1) or BLC (B-lymphocyte chemoattractant), is an efficacious attractant selective for B lymphocytes through binding to the BLR1/CXCR5 receptor[1]. CXCL13 is a homeostatic chemokine, and is constitutively secreted by stromal cells in B-cell areas of secondary lymphoid tissues (follicles), such as spleen, lymph nodes, tonsils, and Peyer's patches[2]. BCA-1/CXCL13 Protein, Mouse (HEK293, His) is produced in HEK293 cells with a N-Terminal His-tag. It consists of 88 amino acids (I22-A109).

  • Application

    SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

  • Biological Activity

    Measured by its ability to chemoattract Ramos cells. The ED50 for this effect is 0.5269 μg/mL, corresponding to a specific activity is 1.897×103 U/mg. Measured by its ability to chemoattract Ramos cells. The ED50 for this effect is 0.5269 μg/mL, corresponding to a specific activity is 1.897×103 U/mg.

  • Alternative Names

    ANGIE; ANGIE2; BCA-1; BCA1; BLC; BLR1L; SCYB13

  • Species

    Mouse

  • Source

    HEK293

  • Tag

    N-His

  • Purity

    Greater than 95% as determined by reducing SDS-PAGE.

  • Uniprot

    O55038

  • Expression Region

    I22-A109

  • Protein Length

    Full Length of Mature Protein

  • Molecular Weight

    16-20 kDa

  • Endotoxin

    < 1.0 EU per μg protein as determined by the LAL method.

  • Form

    Freeze-dried powder

  • Buffer formulation

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • Reconstitution

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • Customization

    Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

  • Stability Test

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • Storage & Shelf Life

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • Shipping

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

BCA-1, also known as CXCL13, is a chemokine that plays a critical role in the immune system by facilitating the migration of B cells to lymphoid tissues. It is primarily produced by lymphoid stromal cells and is essential for the organization of lymphoid follicles. The study of BCA-1/CXCL13 has gained significant attention due to its implications in various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, where aberrant B cell accumulation in tissues contributes to disease pathology. Additionally, the role of BCA-1/CXCL13 in cancer biology, particularly in tumor microenvironments, has emerged as a pivotal area of research, as it may influence tumor progression and metastasis by modulating immune cell infiltration and activation. Recombinant BCA-1/CXCL13 protein is increasingly being utilized in research to dissect its biological functions, understand receptor interactions, and explore its potential as a therapeutic target. Moreover, manipulation of BCA-1/CXCL13 pathways could provide novel strategies for enhancing vaccine responses or developing immunotherapies. By elucidating the mechanisms through which BCA-1/CXCL13 operates, researchers aim to identify new intervention points for diseases characterized by dysregulated immune responses, thereby expanding therapeutic options and improving clinical outcomes.

E-mail

sales@ipodix.com

Sales

+1 2092920560


Contact us via WhatsApp

IPODIX Biotech Inc

2108 N ST, STE N
Sacramento, CA 95816, USA

For Product Information and Orders

sales@ipodix.com

For Business Collaboration

sales@ipodix.com

For CRO Services

sales@ipodix.com

For Technical Support

sales@ipodix.com
  • 50000+

    Recombinant Proteins

  • 100+

    Researchers

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US